Compare Abbott Laboratories (ABT) vs Hasbro, Inc. (HAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Hasbro, Inc. — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Hasbro, Inc. trades at $75.85 (market cap $10.86B). The key difference: Abbott Laboratories is far larger — about 15.4× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| ABT | HAS | |
|---|---|---|
Market Cap | $166.94B | $10.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $105.88 |
52-Week Low | $82.57 | $70.95 |
Enterprise Value | $193.69B | $13.12B |
Dividend Yield | 2.63% | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Hasbro (HAS) trades at $76.73, down 4.27% on the day, with a bearish technical signal but oversold RSI readings suggesting potential reversal. The company reported a net loss of $322.4 million in 2025 despite revenue growth to $4.70 billion, with strong earnings beats in recent quarters. Analyst consensus is bullish with a $107.40 price target, while institutional sentiment remains mixed amid high debt levels and profitability challenges.
The outlook hinges on earnings execution and debt management, with upside from Wizards segment growth and digital initiatives. Key risks include sustained negative margins, $3.38 billion long-term debt burden, and consumer discretionary volatility. Near-term catalyst is Q2 2026 earnings on July 21, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
